Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
10.59
+0.01 (0.09%)
At close: Dec 5, 2025, 4:00 PM EST
10.75
+0.16 (1.51%)
After-hours: Dec 5, 2025, 6:49 PM EST
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Cullinan Therapeutics stock have an average target of 27.14, with a low estimate of 19 and a high estimate of 38. The average target predicts an increase of 156.28% from the current stock price of 10.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cullinan Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 | 6 | 6 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $32 → $38 | Strong Buy | Maintains | $32 → $38 | +258.83% | Nov 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $24 → $26 | Strong Buy | Maintains | $24 → $26 | +145.51% | Nov 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +126.63% | Sep 12, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +202.17% | Sep 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +126.63% | Aug 21, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
26.47M
EPS This Year
-3.84
from -3.11
EPS Next Year
-3.70
from -3.84
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 84.0M | ||||
| Avg | n/a | 26.5M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.65 | -2.99 | ||||
| Avg | -3.84 | -3.70 | ||||
| Low | -3.93 | -4.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.